Navigation Links
Neogen Reports 18% Increase in Net Income
Date:12/18/2009

LANSING, Mich., Dec. 18 /PRNewswire-FirstCall/ -- Neogen Corporation (Nasdaq: NEOG) announced today that its net income for the second quarter of FY 2010, which ended Nov. 30, increased 18% from the previous year's second quarter. Adjusted for a 3-for-2 stock split effective Dec. 15, net income in the quarter rose to $0.20 per share, compared to the prior year's $0.17. Neogen's second quarter net income of $4,610,000 set another quarterly record for the 27-year-old company.

Second quarter revenues increased 13% to $35,251,000, also a quarterly record, compared to the prior year's $31,187,000. Year-to-date revenues for the first six months of fiscal year 2010 rose 13% to $67,598,000 from FY 2009's $59,992,000. Current year-to-date net income for the same six-month period increased 18% to $9,006,000 from $7,634,000 in FY 2009, or to $0.39 per share on a split-adjusted basis compared to the prior year's restated $0.34.

With its 3-for-2 stock split, Neogen's shareholders of record on Nov. 30 received one additional share of stock for each two shares held. The stock dividend was paid in newly issued common stock on Dec. 15. Neogen had 15,000,000 shares of common stock outstanding prior to the split, and now has 22,500,000 shares of common stock outstanding. All share and per-share numbers in this news release reflect the split as if it had taken place at the beginning of the periods presented.

"Our second quarter results were exceptional considering the economic situation encountered by many of our customers. We can report strong double-digit increases in revenues, same-store sales and profitability, while at the same time making solid progress in several fundamental areas during the quarter that will drive future growth," said James Herbert, Neogen's chief executive officer and chairman. "The broad-based advancement of several of our diagnostic and preventative product lines, both domestically and internationally, indicates that our experienced team continues to perfect the business model that has driven our remarkable 19 years of growth."

The second quarter was the 67th consecutive profitable quarter from operations for the company, and the 71st quarter of the past 76 quarters to show increased revenues as compared with the previous year.

"We're extremely pleased to report a 23% increase in operating income for the second consecutive quarter--that's a remarkable achievement at any time, but especially in this economy," said Lon Bohannon, Neogen's president and chief operating officer. "Strong revenue growth and ongoing efforts to control costs and improve productivity have resulted in a decline for many expense categories as a percentage of sales. R & D expense is a notable exception because we continue to view our increased research spending as a critical investment that will help drive future growth."

Operating income as a percentage of sales increased to 20.5% in the current quarter from the previous year's comparable quarter of 18.8%. On a six-month basis, operating income is 21.0% of sales compared to 19.2% in the prior year. Gross margins in the quarter improved to 52.5% of sales in FY 2010, compared to 51.7% in the prior year's second quarter.

"We're also pleased to note that the currency headwinds we faced in previous quarters have abated," said Richard Current, Neogen's chief financial officer. "We also had another excellent quarter in generating cash, with quarter-end cash in excess of $30,000,000. But, note that the financial results that we are reporting today do not reflect the effect of the cash acquisition of the BioKits food safety business from Gen-Probe Incorporated--that acquisition was completed in our third quarter."

Neogen's Food Safety Division led the company's second quarter revenue increase, with sales up 20% from $15,379,000 in FY 2009 to $18,446,000 in FY 2010. Year-to-date, the Food Safety Division's revenues were up 16% to $35,921,000 for FY 2010. Sales growth in Food Safety was broad-based across multiple market segments and product lines for the quarter and on a year-to-date basis. Neogen's line of drug residue tests, led by sales of tests for dairy antibiotic residues increased significantly due to increased sales of higher value test kits, overall unit volume growth, and a relatively positive currency exchange rate for test kits sold in Euros.

Cool, wet weather conditions experienced throughout parts of the U.S. corn belt during the summer and fall led to sharp increases in demand for test kits to detect the presence of mycotoxins, especially vomitoxin. Sales of the company's Acumedia dehydrated culture media products improved over FY 2009's second quarter, as sales to traditional media customers and international distributors achieved double-digit organic growth. Food allergen test kit sales also continued their recent trend of strong same-store sales growth in the second quarter with an increase in excess of 20% compared to the prior year.

Neogen's Animal Safety Division second quarter revenues increased 6% to $16,805,000, compared to $15,808,000 in the previous fiscal year. For FY 2010's first six months, the Animal Safety Division's sales increased 9% over the comparable period last year to $31,677,000. Sales of Neogen's rodenticides, cleaners and disinfectants in the quarter increased 22% over the prior year primarily due to successful marketing programs for rodenticide products and a strong increase in domestic sales of disinfectants. Sales of the company's Kare line of companion animal products sold through ethical distribution channels also exhibited strong growth for the quarter.

The internal development and release of four new products in the second quarter, and the May 2009 acquisition of International Diagnostic Systems, led to a 26% quarter-over-quarter increase in sales of Animal Safety's diagnostic products. Sales of test kits used to detect drugs of abuse in the forensics market and sales derived from contract research and supply agreements both achieved significant growth.

Neogen's acquisition of the BioKits food safety business of Gen-Probe Incorporated was completed on the first day of Neogen's third quarter, Dec. 1. The acquisition includes more than 50 test kits for food allergens, meat and fish speciation, and plant genetics. The U.K.-based business is now a part of Neogen Europe Ltd., which is headquartered in Ayr, Scotland.

Neogen Corporation develops and markets products dedicated to food and animal safety. The company's Food Safety Division markets dehydrated culture media, and diagnostic test kits to detect foodborne bacteria, natural toxins, genetic modifications, food allergens, drug residues, plant diseases and sanitation concerns. Neogen's Animal Safety Division markets a complete line of diagnostics, veterinary instruments, veterinary pharmaceuticals, nutritional supplements, disinfectants, and rodenticides.

Certain portions of this news release that do not relate to historical financial information constitute forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties. Actual future results and trends may differ materially from historical results or those expected depending on a variety of factors listed in Management's Discussion and Analysis of Financial Condition and Results of Operations in the Company's most recently filed Form 10-K.


    NEOGEN CORPORATION UNAUDITED SUMMARIZED CONSOLIDATED OPERATING DATA
                   (In thousands, except for per share and percentages)

                                     Quarter ended          Six months ended
                                         Nov. 30                 Nov. 30
                                   2009          2008         2009      2008

    Revenue
      Food Safety               $18,446       $15,379      $35,921   $30,928
      Animal Safety              16,805        15,808       31,677    29,064
                                 ------        ------       ------    ------
    Total revenue                35,251        31,187       67,598    59,992
    Cost of sales                16,729        15,062       31,806    29,063
                                 ------        ------       ------    ------
    Gross margin                 18,522        16,125       35,792    30,929
    Other expenses
      Sales & marketing           6,405         6,013       12,377    11,632
      Administrative              3,191         3,032        6,082     5,612
      Research &
       development                1,698         1,219        3,161     2,171
                                  -----         -----        -----     -----
    Total other expenses         11,294        10,264       21,620    19,415
                                 ------        ------       ------    ------
    Operating income              7,228         5,861       14,172    11,514
    Other revenue                   (18)          240           34       445
                                    ---           ---          ---       ---
    Income before tax             7,210         6,101       14,206    11,959
    Income tax                    2,600         2,200        5,200     4,325
                                  -----         -----        -----     -----
    Net income                   $4,610        $3,901       $9,006    $7,634
    Net income per
     diluted share (1)            $0.20         $0.17        $0.39     $0.34

    Other information:
      Shares to calculate
       per share (1)             23,026        22,683       22,916    22,613
      Depreciation &
       amortization              $1,016        $1,002       $2,028    $1,950
      Interest income                16            69           33       134
      Gross margin
       (% of sales)                52.5%         51.7%        52.9%     51.6%
      Operating income
      (% of sales)                 20.5%         18.8%        21.0%     19.2%
      Revenue increase vs.
       FY 2009                     13.0%                      12.7%
      Net income increase vs.
       FY 2009                     18.2%                      18.0%


    NEOGEN CORPORATION UNAUDITED SUMMARIZED CONSOLIDATED BALANCE SHEET DATA
                                    (In thousands)

                                                        Nov. 30        May 31
                                                           2009          2009

    Assets
    Current assets
      Cash & investments                                $32,454       $13,842
      Accounts receivable                                25,176        23,363
      Inventory                                          30,149        31,363
      Other current assets                                3,255         3,198
                                                          -----         -----
    Total current assets                                 91,034        71,766
    Property & equipment                                 16,718        17,058
    Goodwill & other assets                              53,161        53,352
                                                         ------        ------
    Total assets                                       $160,913      $142,176

    Liabilities & Stockholders' Equity
    Current liabilities                                 $14,968        $9,246
    Long-term debt                                            -             -
    Other long-term liabilities                           4,321         4,251
    Stockholders' equity-shares outstanding
      22,491 in Nov. & 22,105 in May (1)                141,624       128,679
                                                        -------       -------
    Total liabilities & stockholders' equity           $160,913      $142,176

    (1) Reflects effect of Dec 15, 2009, 3-for-2 stock split

SOURCE Neogen Corporation


'/>"/>
SOURCE Neogen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Richard T. Crowder Joins Neogens Board of Directors
2. Neogen Announces 3 for-2 Stock Split
3. Neogen to Ring NASDAQs Closing Bell
4. NeoGenomics To Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 18, 2009
5. Neogen Again Named to Forbes List of Best Small Companies
6. Neogen Reports 18% Increase in Net Income, 12% Increase in Revenues
7. NeoGenomics to Present at the Rodman & Renshaw Healthcare Investment Conference on September 10, 2009
8. NeoGenomics Reports Second Quarter 2009 Results
9. Neogen Reports 16% Increase in Revenues
10. Neogen Corporation Announces Year-End Results Conference Call
11. Neogen Named to Fortunes List of Fastest Growing Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
(Date:6/23/2016)... June 23, 2016 A person commits a crime, ... scene to track the criminal down. An outbreak ... and Drug Administration (FDA) uses DNA evidence to track down ... Sound far-fetched? It,s not. The FDA has increasingly used ... investigations of foodborne illnesses. Put as simply as possible, whole ...
(Date:6/23/2016)... 2016   EpiBiome , a precision microbiome engineering ... debt financing from Silicon Valley Bank (SVB). The financing ... advance its drug development efforts, as well as purchase ... "SVB has been an incredible strategic partner to us ... bank would provide," said Dr. Aeron Tynes Hammack ...
Breaking Biology Technology:
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):